Presbyopia Treatment: DCGI Suspends Entod Pharma’s Eye Drop Approval

Wednesday, 11 September 2024, 04:32

Presbyopia treatment claims by Entod Pharma regarding their eye drop 'PresVu' have been suspended by the DCGI. Violations of approved promotional guidelines and unauthorized claims have led to this suspension. Medical experts have raised concerns about the safety and regulatory compliance of the product.
Financialexpress
Presbyopia Treatment: DCGI Suspends Entod Pharma’s Eye Drop Approval

Presbyopia Treatment Claims Controversy

Days after Entod Pharmaceuticals claimed their eye drop PresVu could reduce dependency on reading glasses, the Drug Controller General of India (DCGI) suspended its approval. This decision followed allegations that the company had not obtained the necessary permissions to market the product properly.

Violation of Regulations

In an order issued on September 10, the DCGI cited violations of the New Drugs and Clinical Trial Rules, 2019 for unauthorized promotion. Despite receiving CDSCO approval, Entod's promotional activities led to public safety concerns.

  • Presbyopia impacts those over 40, complicating vision; hence, its treatment is vital.
  • DCGI pointed out that the product was marketed as an OTC drug despite being a prescription-only treatment.

Company’s Stance

Entod Pharmaceuticals maintains that all media disclosures are based on appropriate approvals. Their CEO, Nikkhil K Masurkar, indicated a willingness to challenge the suspension in court, emphasizing a commitment to bringing innovative treatments to India.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe